About us: Leadership

Pierre-Henry Longeray, PharmD, MBA, has more than 20 years of experience as General Manager/CEO in the HealthCare and Life Sciences Industries. He has made his career at Lipha and Theramex and in recent years at Merck, a global LiveScience and Technology company. He successfully managed Merck's Biopharma activities in France, the group's leading European subsidiary, and then all Merck's activities in France. His career has led him to manage internal and external growth operations, major transformations and restructuring, and innovation launches for the group in Oncology, Neurology, Rare Diseases, and Women's Health. He held also international responsibilities (Head of International Strategic Products Management and Global Women's Health Business Unit Head). He has also been involved in the Leem (the professional organization for pharmaceutical companies in France) and ARIIS (Alliance pour la Recherche et l'Innovation de Industries de Santé), of which he was a member of the Executive Committee and the Board of Directors. In March 2019, he joined Igyxos as CEO.

Marie-Christine Maurel received a Master of Science degree in Biological Sciences and a Ph.D. in Reproductive Physiology from Pierre & Marie Curie University in Paris, France. She also served as a post-doctoral fellow in Immunology at the Institute Pasteur in Paris. She has more than 25 years' experience as scientist at INRA (National Institute of Agronomic Research) in the fertility field and 10 years' biotech experience since 2012. Her research activity focused on the endocrinology of reproduction, especially on the biochemistry and immunogenic properties of pituitary gonadotropic hormones (FSH, LH and CG).

​

In 2009 she was the winner of the french "National competition for the creation of innovative companies" and founded ReproPharm®, a biotech company based at the INRA center of Tours, France. Since 2012 she was CEO and scientific director at ReproPharm.

​

In 2017, she splitted Repropharm's activities and founded two new and independent companies: Repropharm Vet® for the development of therapeutics in animal health and Igyxos® for the development of therapeutics in human health. Currently, she is the Chief Scientific Officer of Igyxos and the Chaiman of the Board of Directors.

​

In 2011, the French Government nominated her for the Chevalier degree by the National Order of the Legion of Honour, which is the highest order of merit in France.

Thierry Ziegler has more than 25 years of experience in biopharmaceutical development. Prior to joining Igyxos, he led cell therapy production activities at Cellectis. Previously, Dr. Ziegler also served as Head of Process Development at Merck-Serono, as well as head of biopharmaceutical development at Sanofi. During his career, he had the opportunity to work on multiple monoclonal antibodies as well as many other types of Biologics modalities ranging from recombinant proteins to CAR-T cells. He joined Igyxos in February 2021 as Chief Operating Officer to oversee subcontracted activities related to the development of IGX12. In this role, Dr. Ziegler oversees IGX12 CMC development from cell line generation to GMP manufacturing. He received his Ph.D. in bioprocess engineering from the Georgia Institute of Technology in the United States.